Oral bioavailability of candesartan cilexetil suspension

Journal of Pharmacy Technology

Volumn 23, Issue 5, 2007, Pages 270-274

  Teng, Renli ^a   Hansson, Anna Carin ^a   Börjesson, Inger ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN HEXETIL; CREATINE KINASE; LIVER ENZYME;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DRUG BIOAVAILABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSPENSION; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

EID: 35148832726     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250702300503     Document Type: Article

References (8)

1. Flynn JT. Pharmacologic management of childhood hypertension: current status, future challenges. Am J Hypertens 2002;15(suppl):30S-3S.
2. National high blood pressure education program. Update on the 1987 task force report on high blood pressure in children and adolescents: a working group report from the national high blood pressure education program. Pediatrics 1996;98:649-58.
3. Blowey DL. Antihypertensive agents: mechanisms of action, safety profiles, and current uses in children. Curr Ther Res 2001;62:298-313.
4. Tanser PH, Campbell LM, Carranza J, Karrash J, Toutouzas P, Watts R. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Am J Hypertens 2000;13:214-8.
5. Zanchetti A, Omboni S, Di Biagio C. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens 1997;11:S57-9.
6. Sakarcan A, Tenney F, Wilson JT,, et al. The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 2001;41:742-9.
7. VonVigier RO, Zberg PM, Teuffel O, Bianchetti MG. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. Eur J Pediatr 2000;159:590-3.
8. Stenhoff H, Lagerström PO, Andersen C. Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection. J Chromatogr B 1999;731:411-7.